Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors

Seminars in Nuclear Medicine

Volumn 40, Issue 2, 2010, Pages 78-88

  Kwekkeboom, Dik J ^a   de Herder, Wouter W ^a   van Eijck, Casper H J ^a   Kam, Boen L ^a   van Essen, Martijn ^a   Teunissen, Jaap J M ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BEVACIZUMAB; CAPECITABINE; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; IMATINIB; IRINOTECAN; MITOXANTRONE; OCTREOTATE LU 177; OCTREOTATE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; OCTREOTHER; OCTREOTIDE; OCTREOTIDE PENTETATE IN 111; OCTREOTIDE PENTETIC ACID; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; OXALIPLATIN; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ABDOMINAL DISCOMFORT; BLOOD TOXICITY; CANCER PATIENT; CARCINOID; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HAIR LOSS; HUMAN; LEUKEMIA; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PAIN; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; QUALITY OF LIFE; RADIATION DOSE; RENAL PROTECTION; REVIEW; SELF EVALUATION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ANIMALS; HUMANS; NEUROENDOCRINE TUMORS; QUALITY OF LIFE; RADIOTHERAPY; RECEPTORS, SOMATOSTATIN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 74849111472     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.10.004     Document Type: Review

References (68)

1. Krenning E.P., Bakker W.H., Breeman W.A., et al. Localization of endocrine related tumors with radioiodinated analogue of somatostatin. Lancet 1 (1989) 242-245
2. Arnold R., Benning R., Neuhaus C., et al. Gastroenteropancreatic endocrine tumours: Effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54 suppl 1 (1993) 72-75
3. Janson E.T., and Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32 (1993) 225-229
4. Ducreux M., Ruszniewski P., Chayvialle J.A., et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95 (2000) 3276-3281
5. 0]octreotide: The Rotterdam experience. Semin Nucl Med 32 (2002) 110-122
6. Kwekkeboom D.J., Mueller-Brand J., Paganelli G., et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 suppl 1 (2005) 62S-66S
7. Anthony L.B., Woltering E.A., Espanan G.D., et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32 (2002) 123-132
8. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12 (2001) 941-945
9. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43 (2002) 610-616
10. Waldherr C., Schumacher T., Maecke H.R., et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors?. (abstract). Eur J Nucl Med Mol Imaging 29 suppl 1 (2002) S100
11. 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 30 (2003) 207-216
12. Valkema R., Pauwels S., Kvols L.K., et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36 (2006) 147-156
13. 3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26 (2008) 2124-2130
14. Otte A., Herrmann R., Heppeler A., et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 26 (1999) 1439-1447
15. Chinol M., Bodei L., Cremonesi M., et al. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: The experience of the European Institute of Oncology group. Semin Nucl Med 32 (2002) 141-147
16. Paganelli G., Bodei L., Handkiewicz Junak D., et al. 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66 (2002) 393-398
17. Valkema R., Pauwels S., Kvols L., et al. Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0, Tyr3]octreotide in patients with somatostatin receptor positive tumours (abstract). Eur J Nucl Med Mol Imaging 30 suppl 2 (2003) S232
18. 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 44 (2003) 1556-1560
19. de Jong M., Breeman W.A., Bakker W.H., et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58 (1998) 437-441
20. Erion J.L., Bugaj J.E., Schmidt M.A., et al. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model (abstract). J Nucl Med 40 suppl (1999) 223
21. Reubi J.C., Schaer J.C., Waser B., et al. Affinity profiles for human somatostatin receptor SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
22. Kwekkeboom D.J., Bakker W.H., Kooij P.P., et al. [177Lu-DOTA0Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28 (2001) 1319-1325
23. Esser J.P., Krenning E.P., Teunissen J.J., et al. Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: Which peptide is preferable for PRRT?. Eur J Nucl Med Mol Imaging 33 (2006) 1346-1351
24. Kwekkeboom D.J., Bakker W.H., Kam B.L., et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 30 (2003) 417-422
25. 3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors. J Clin Oncol 23 (2005) 2754-2762
26. De Keizer B., van Aken M.O., Feelders R.A., et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 35 (2008) 749-755
27. Teunissen J.J., Kwekkeboom D.J., and Krenning E.P. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 22 (2004) 2724-2729
28. Virgolini I., Britton K., Buscombe J., et al. 111In- and 90Y-DOTA-Lanreotide: Results and implications of the Mauritius trial. Semin Nucl Med 32 (2002) 148-155
29. Wehrmann C., Senftleben S., Zachert C., et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 22 (2007) 406-416
30. Baum R.P., Soldner J., Schmucking M., et al. Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga. Der Onkologe 10 (2004) 1098-1110
31. Baum R.P., Soldner J., Schmucking M., et al. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors (abstract). Eur J Nucl Med 31 suppl 2 (2004) S238
32. Clancy T.E., Sengupta T.P., Paulus J., et al. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51 (2006) 877-884
33. Janson E.T., Holmberg L., Stridsberg M., et al. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8 (1997) 685-690
34. Quaedvlieg P.F., Visser O., Lamers C.B., et al. Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12 (2001) 1295-1300
35. Mazzaglia P.J., Berber E., Milas M., et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: A 10-year experience evaluating predictors of survival. Surgery 142 (2007) 10-19
36. Faiss S., Pape U.F., Bohmig M., et al. International Lanreotide and Interferon Alfa Study Group: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 (2003) 2689-2696
37. Bukowski R.M., Tangen C.M., Peterson R.F., et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 73 (1994) 1505-1508
38. Ritzel U., Leonhardt U., Stockmann F., et al. Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 90 (1995) 627-631
39. Andreyev H.J., Scott-Mackie P., Cunningham D., et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 13 (1995) 1486-1492
40. Neijt J.P., Lacave A.J., Splinter T.A., et al. Mitoxantrone in metastatic apudomas: A phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. Br J Cancer 71 (1995) 106-108
41. Cheng P.N., and Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 (1999) 944-948
42. Ansell S.M., Pitot H.C., Burch P.A., et al. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91 (2001) 1543-1548
43. O'Toole D., Hentic O., Corcos O., et al. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 80 suppl 1 (2004) 79-84
44. Moertel C.G., Hanley J.A., and Johnson L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Eng J Med 303 (1980) 1189-1194
45. Moertel C.G. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1 (1993) 727-740
46. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
47. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (2004) 4762-4771
48. Sun W., Lipsitz S., Catalano P., et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 23 (2005) 4897-4904
49. Ducreux M.P., Boige V., Leboulleux S., et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology 70 (2006) 134-140
50. Bajetta E., Catena L., Procopio G., et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol 59 (2007) 637-642
51. Ekeblad S., Sundin A., Janson E.T., et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13 (2007) 2986-2991
52. Strosberg J.R., Choi J., Gardner N., et al. First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide (abstract). J Clin Oncol 26 suppl (2008) 4612
53. Kulke M.H., Stuart K., Earle C.C., et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors (abstract). J Clin Oncol 24 suppl (2006) 4044
54. Hobday T.J., Rubin J., Holen K., et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study (abstract). J Clin Oncol 25 suppl (2007) 4504
55. Yao J.C., Zhang J.X., Rashid A., et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13 (2007) 234-240
56. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26 (2008) 3403-3410
57. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95 (2006) 1148-1154
58. Yao J.C., Phan A.T., Chang D.Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 26 (2008) 4311-4318
59. De Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
60. Wong J.Y., Shibata S., Williams L.E., et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 9 (2003) 5842-5852
61. Kong G., Lau E., Ramdave S., et al. High-dose In-111 octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors (abstract). J Nucl Med 46 suppl 2 (2005) 151P
62. Rich T.A., Shepard R.C., and Mosley S.T. Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22 (2004) 2214-2232
63. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20 (2002) 3983-3991
64. Van Essen M., Krenning E.P., Kam B.L., et al. Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 35 (2008) 743-748
65. Förrer F, Krenning EP, Kooij PP, et al: Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging (in press)
66. Valkema R., Pauwels S.A., Kvols L.K., et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177). Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 46 suppl 1 (2005) 83S-91S
67. Bodei L., Cremonesi M., Ferrari M., et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med Mol Imaging 35 (2008) 1847-1856
68. Konijnenberg M., Melis M., Valkema R., et al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 48 (2007) 134-142